CN103269716B - 冻干病毒制剂 - Google Patents

冻干病毒制剂 Download PDF

Info

Publication number
CN103269716B
CN103269716B CN201180062149.7A CN201180062149A CN103269716B CN 103269716 B CN103269716 B CN 103269716B CN 201180062149 A CN201180062149 A CN 201180062149A CN 103269716 B CN103269716 B CN 103269716B
Authority
CN
China
Prior art keywords
virus
liquid
viral
viral composition
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180062149.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN103269716A (zh
Inventor
M.C.科菲
S.塞尔
L.帕夫利夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ankolitix Biotechnology Barbados Co
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of CN103269716A publication Critical patent/CN103269716A/zh
Application granted granted Critical
Publication of CN103269716B publication Critical patent/CN103269716B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12251—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201180062149.7A 2010-12-02 2011-12-02 冻干病毒制剂 Active CN103269716B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41902010P 2010-12-02 2010-12-02
US61/419020 2010-12-02
PCT/US2011/063037 WO2012075376A2 (en) 2010-12-02 2011-12-02 Lyophilized viral formulations

Publications (2)

Publication Number Publication Date
CN103269716A CN103269716A (zh) 2013-08-28
CN103269716B true CN103269716B (zh) 2015-05-27

Family

ID=46162458

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180062149.7A Active CN103269716B (zh) 2010-12-02 2011-12-02 冻干病毒制剂

Country Status (15)

Country Link
US (2) US9044498B2 (https=)
EP (1) EP2646052B1 (https=)
JP (3) JP6034797B2 (https=)
KR (1) KR102023207B1 (https=)
CN (1) CN103269716B (https=)
AU (1) AU2011336410B2 (https=)
CA (1) CA2819236A1 (https=)
DK (1) DK2646052T3 (https=)
EA (1) EA201390812A1 (https=)
ES (1) ES2630012T3 (https=)
IL (1) IL226646B (https=)
MX (1) MX349294B (https=)
SG (1) SG190419A1 (https=)
TW (1) TW201233803A (https=)
WO (1) WO2012075376A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5577103B2 (ja) * 2007-03-12 2014-08-20 オンコリティクス バイオテク，インコーポレーテッド 改変配列を有するレオウイルス
AU2011336413B2 (en) * 2010-12-02 2015-01-22 Oncolytics Biotech Inc. Liquid viral formulations
MX349294B (es) * 2010-12-02 2017-07-21 Oncolytics Biotech Inc Formulaciones virales liofilizadas.
JP6029651B2 (ja) * 2011-04-29 2016-11-24 オンコリティクス バイオテク，インコーポレーテッド ゲル浸透クロマトグラフィーを使用してウイルスを精製する方法
US11273127B2 (en) 2014-05-06 2022-03-15 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for thermally stable multi-targeted antigens
GB201513010D0 (en) * 2015-07-23 2015-09-09 Glaxosmithkline Biolog Sa Novel formulation
PT3534922T (pt) * 2016-11-04 2024-06-07 Takeda Pharmaceuticals Co Formulações de vírus adenoassociado
CN111655844B (zh) * 2017-10-16 2024-05-24 印度血清研究所私人有限公司 包含特别是减毒活重组黄病毒的稳定的疫苗组合物及其制备方法
AU2019299964A1 (en) 2018-07-11 2021-01-21 Takeda Pharmaceutical Company Limited AAV compositions
CN110279693B (zh) * 2019-07-25 2021-06-15 军事科学院军事医学研究院微生物流行病研究所 一种组合物在制备预防和/或治疗发热伴血小板减少综合征病毒的药物中的应用
CN112107678B (zh) * 2020-09-30 2022-11-18 辰欣药业股份有限公司 一种含有胸腺法新的冻干组合物及其制备方法
CN116270500B (zh) * 2021-12-30 2025-05-06 安徽贝金基因科技有限公司 一种高稳定性的溶瘤病毒组合物及其制备方法和其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948411A (en) * 1992-05-05 1999-09-07 The Research Foundation For Microbial Diseases Of Osaka University Stabilized live vaccine
US6290967B1 (en) * 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
US20050186225A1 (en) * 2000-03-07 2005-08-25 Evans Robert K. Adenovirus formulations
US20080241187A1 (en) * 2004-12-23 2008-10-02 Paramount Biosciences Llc Stabilization of viral compositions
US20100247573A1 (en) * 2006-11-07 2010-09-30 Sanofi Pasteur Biologics Co. Stabilization of Vaccines by Lyophilization

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5626851A (en) 1987-11-30 1997-05-06 The Wistar Institute Of Anatomy And Biology Rotavirus reassortant vaccine
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
DE69029765T2 (de) 1989-07-24 1997-05-15 Bayer Ag Stabilisierung von hochgereinigten Proteinen
CA2132328C (en) 1992-03-24 2000-10-31 Laszlo K. Csatary Vaccine containing live virus for therapy of viral diseases and malignancies
JPH09504429A (ja) 1993-10-12 1997-05-06 チロン ビアジーン，インコーポレイティド 組換えウイルスの保存方法
JP3863559B2 (ja) 1994-05-16 2006-12-27 メルク エンド カンパニー インコーポレーテッド 乳頭腫ウィルスワクチン
US7150984B2 (en) 1994-07-11 2006-12-19 The United States Of America As Represented By The Department Of Health And Human Services Attenuated human rotavirus vaccine
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
GB9521806D0 (en) 1995-10-25 1996-01-03 Cortecs Ltd Preservation methods
US6165773A (en) 1995-10-25 2000-12-26 Provalis Uk Limited Methods of preserving viruses
FR2742756B1 (fr) 1995-12-22 1998-04-03 Pasteur Merieux Serums Vacc Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
US5932223A (en) * 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations
EP0939648B1 (en) 1996-09-26 2007-11-07 Merck & Co., Inc. Rotavirus vaccine formulations
US6403098B1 (en) 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
US6616931B1 (en) 1996-09-26 2003-09-09 Merck & Co., Inc. Rotavirus vaccine formulations
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6544769B1 (en) 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
US20080261289A1 (en) 1996-12-13 2008-10-23 Schering-Plough Corporation Compositions comprising viruses and methods for concentrating virus preparations
US6051238A (en) 1996-12-20 2000-04-18 Merck & Co., Inc. Stabilizers for lyophilized mumps vaccines
JP2000507963A (ja) 1996-12-20 2000-06-27 メルク エンド カンパニー インコーポレーテッド 凍結乾燥ワクチン用安定剤
KR100912362B1 (ko) 1998-02-17 2009-08-19 쉐링 코포레이션 바이러스 제제의 정제방법
GB9808922D0 (en) * 1998-04-24 1998-06-24 Cantab Pharmaceuticals Res Ltd Virus preparations
CN101318016B (zh) 1998-07-28 2013-06-19 由卫生与公众服务部代表的美利坚合众国 多价人-牛轮状病毒疫苗
CN1062770C (zh) * 1998-11-12 2001-03-07 卫生部长春生物制品研究所 甲肝-麻疹二联疫苗及其生产方法
DE69940354D1 (de) 1998-11-16 2009-03-12 Introgen Therapeutics Inc Adenovirus-formulierungen zur gentherapie
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
WO2000061184A2 (en) 1999-04-08 2000-10-19 Glenn Gregory M Dry formulation for transcutaneous immunization
PL364983A1 (en) 1999-08-24 2004-12-27 Teva Pharmaceutical Industries, Ltd. A vaccine composition and method of using the same
US6592869B2 (en) 1999-08-24 2003-07-15 Teva Pharmaceutical Industries, Ltd. Vaccine composition and method of using the same
DE60025019T2 (de) 1999-10-29 2006-08-24 Nektar Therapeutics, San Carlos Trockenpulverzusammensetzungen mit verbesserter dispersivität
EP2420247A1 (en) 2000-03-07 2012-02-22 Merck Sharp & Dohme Corp. Adenovirus formulations
EP1289494A2 (en) 2000-06-08 2003-03-12 Powderject Vaccines, Inc. Powder compositions
US20020120228A1 (en) 2000-06-08 2002-08-29 Yuh-Fun Maa Powder compositions
TWI289158B (en) 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
GB0020089D0 (en) 2000-08-15 2000-10-04 Smithkline Beecham Biolog Vaccine Composition
US7494659B2 (en) 2000-09-25 2009-02-24 Polymun Scientific Immunbiologische Forschung Gmbh Live attenuated influenza vaccine
US20040033239A1 (en) 2001-03-06 2004-02-19 Evans Robert K Adenovirus formulations
DK2253701T3 (da) 2001-03-16 2014-10-20 Oncolytics Biotech Inc Fremgangsmåde til ekstraktion af en virus fra en cellekultur
CA2449593A1 (en) 2001-06-08 2002-12-19 Powderject Vaccines, Inc. Spray freeze-dried compositions
GB0124710D0 (en) 2001-10-15 2001-12-05 Quadrant Healthcare Uk Ltd Therapeutic composition
CN1607941A (zh) 2001-11-19 2005-04-20 贝克顿迪肯森公司 粒状药物组合物
EP1453536A4 (en) 2001-12-12 2009-08-26 Mayne Pharma Int Pty Ltd COMPOSITION FOR PRESERVING VIRUSES
US20030153065A1 (en) 2002-01-14 2003-08-14 Genvec, Inc. Composition and method for maintaining non-enveloped viral vectors
AR038153A1 (es) 2002-01-18 2004-12-29 Schering Ag Formulaciones estabilizadas de adenovirus
WO2003086443A1 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
US7923029B2 (en) 2002-04-11 2011-04-12 Medimmune Llc Spray freeze dry of compositions for pulmonary administration
US7135180B2 (en) 2002-04-11 2006-11-14 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
CA2482512C (en) 2002-04-30 2011-09-20 Oncolytics Biotech Inc. Improved viral purification methods
EP2395073B1 (en) 2002-11-01 2017-09-06 GlaxoSmithKline Biologicals S.A. Drying process
US6752740B2 (en) 2002-11-12 2004-06-22 Jeffery T. Semmes Continuously variable transmission
KR20050088175A (ko) 2002-12-17 2005-09-02 메드이뮨 백신즈 인코포레이티드 생물활성 물질의 고압 분무 건조
US6931888B2 (en) 2003-02-07 2005-08-23 Ferro Corporation Lyophilization method and apparatus for producing particles
ES2529736T3 (es) 2003-04-10 2015-02-25 Novartis Vaccines And Diagnostics, Inc. Composición inmunogénica que comprende una proteína espicular del coronavirus del SARS
EP1660123B1 (en) * 2003-09-02 2013-03-13 GlaxoSmithKline Biologicals s.a. Rotavirus vaccine
US20070148765A1 (en) 2003-11-19 2007-06-28 Evans Robert K Preservative-containing virus formulations
EP1701738B1 (en) 2003-12-17 2015-03-11 Wyeth LLC Method for producing storage stable RSV compositions
WO2005066333A1 (en) 2003-12-30 2005-07-21 Aventis Pasteur, Inc. Stabilizing compositions for recombinant viruses
GB0404586D0 (en) 2004-03-01 2004-04-07 Britannia Pharmaceuticals Ltd Improvements in or relating to organic materials
EP1720519A1 (en) 2004-03-04 2006-11-15 Wyeth Lyophilization method to improve excipient crystallization
ES2644416T3 (es) 2004-06-02 2017-11-28 Universal Stabilization Technologies, Inc. Conservación mediante vaporización
WO2006029467A1 (en) 2004-09-16 2006-03-23 Btf Pty Ltd Rapid freeze drying process
TW200626177A (en) 2004-09-28 2006-08-01 Alza Corp Method and formulation for stabilizing alum-adsorbed vaccines
US7901921B2 (en) 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
MX2007005379A (es) * 2004-11-05 2007-07-04 Wellstat Biologics Corp Formulaciones de virus envueltos estables y filtrables.
ATE406140T1 (de) 2004-12-09 2008-09-15 Precimed Sa Operationsinstrumentenhalter für leichtere sterilisation
SI1853250T1 (sl) 2005-02-18 2012-01-31 Abraxis Bioscience Llc Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija
PT1954308E (pt) * 2005-09-16 2011-11-03 Merial Ltd Estabilizadores para vacinas liofilizadas
CN1765181A (zh) 2005-10-19 2006-05-03 路兴波 高效抗病毒制剂
PL2007883T3 (pl) 2006-04-20 2012-07-31 Wyeth Llc Sposób oczyszczania do izolacji oczyszczonego wirusa pęcherzykowatego zapalenia jamy ustnej z hodowli komórkowej
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
EP1854478A1 (en) 2006-05-12 2007-11-14 Cytos Biotechnology AG Nicotine-carrier vaccine formulation
EP1878791A1 (en) 2006-07-11 2008-01-16 Bia Separations D.O.O. Method for influenza virus purification
EP2055311B1 (en) 2006-08-07 2017-06-21 The Chemo-Sero-Therapeutic Research Institute Process for preparing live smallpox vaccine
US20100129379A1 (en) 2006-09-25 2010-05-27 John Carpenter Stabilized antibody formulations and uses thereof
NZ576563A (en) 2006-11-03 2012-09-28 Alphavax Inc Alphavirus and alphavirus replicon particle formulations and methods
EP2762163B1 (en) 2006-12-27 2018-01-03 Zoetis Services LLC Methods of vaccine administration
US20080299182A1 (en) 2007-03-01 2008-12-04 Shuyuan Zhang Methods and formulations for topical gene therapy
JP5577103B2 (ja) * 2007-03-12 2014-08-20 オンコリティクス バイオテク，インコーポレーテッド 改変配列を有するレオウイルス
GB0705245D0 (en) 2007-03-19 2007-04-25 Stabilitech Ltd Stable biological products
CA2681567C (en) * 2007-03-22 2016-07-19 The Regents Of The University Of Colorado, A Body Corporate Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
EP2940129B1 (en) 2007-04-06 2020-05-06 Takeda Vaccines, Inc. Methods and compositions for live attenuated viruses
AR066649A1 (es) 2007-05-21 2009-09-02 Oncolytics Biotech Inc Reovirus mutantes y metodos de elaboracion y uso de los mismos
US8241886B2 (en) * 2007-09-25 2012-08-14 Aridis Pharmaceuticals Formulations for preservation of rotavirus
EP2630966B1 (en) 2007-10-12 2017-04-19 Massachusetts Institute of Technology Vaccine nanotechnology
WO2009056651A1 (en) 2007-11-02 2009-05-07 Cytos Biotechnology Ag Angiotensin-carrier formulation
NZ585500A (en) 2007-11-12 2012-06-29 Theraclone Sciences Inc Antibodies which bind to an epitope in the extracellular domain of the matrix 2 ectodomain polypeptide of an influenza virus
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
JP2011514337A (ja) * 2008-02-25 2011-05-06 ノババックス，インコーポレイテッド 糖ガラス化ウィルス様粒子（ｖｌｐ）
WO2011026948A1 (en) * 2009-09-03 2011-03-10 Ablynx N.V. Stable formulations of polypeptides and uses thereof
AU2011336413B2 (en) * 2010-12-02 2015-01-22 Oncolytics Biotech Inc. Liquid viral formulations
MX349294B (es) * 2010-12-02 2017-07-21 Oncolytics Biotech Inc Formulaciones virales liofilizadas.
JP6029651B2 (ja) * 2011-04-29 2016-11-24 オンコリティクス バイオテク，インコーポレーテッド ゲル浸透クロマトグラフィーを使用してウイルスを精製する方法
JP6065096B2 (ja) 2015-12-25 2017-01-25 ダイキン工業株式会社 調湿装置

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948411A (en) * 1992-05-05 1999-09-07 The Research Foundation For Microbial Diseases Of Osaka University Stabilized live vaccine
US6290967B1 (en) * 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
US20050186225A1 (en) * 2000-03-07 2005-08-25 Evans Robert K. Adenovirus formulations
US20080241187A1 (en) * 2004-12-23 2008-10-02 Paramount Biosciences Llc Stabilization of viral compositions
US20100247573A1 (en) * 2006-11-07 2010-09-30 Sanofi Pasteur Biologics Co. Stabilization of Vaccines by Lyophilization

Also Published As

Publication number Publication date
CA2819236A1 (en) 2012-06-07
JP6034797B2 (ja) 2016-11-30
WO2012075376A2 (en) 2012-06-07
JP6433954B2 (ja) 2018-12-05
MX2013006169A (es) 2013-10-28
US9610352B2 (en) 2017-04-04
JP2016199591A (ja) 2016-12-01
JP2013544288A (ja) 2013-12-12
EP2646052B1 (en) 2017-03-29
EP2646052A4 (en) 2014-01-08
JP2018172443A (ja) 2018-11-08
US9044498B2 (en) 2015-06-02
US20150224198A1 (en) 2015-08-13
MX349294B (es) 2017-07-21
CN103269716A (zh) 2013-08-28
WO2012075376A3 (en) 2012-08-16
SG190419A1 (en) 2013-06-28
DK2646052T3 (en) 2017-07-17
KR20140014096A (ko) 2014-02-05
ES2630012T3 (es) 2017-08-17
US20120141528A1 (en) 2012-06-07
AU2011336410B2 (en) 2015-01-22
EA201390812A1 (ru) 2013-11-29
EP2646052A2 (en) 2013-10-09
IL226646B (en) 2018-02-28
KR102023207B1 (ko) 2019-11-25
AU2011336410A1 (en) 2013-03-28
TW201233803A (en) 2012-08-16

Similar Documents

Publication Publication Date Title
CN103269716B (zh) 冻干病毒制剂
CN103347535B (zh) 液体病毒制剂
DK1937244T3 (en) : CANCER TREATMENT WITH SPECIFIC RXR AGONISTS
HK1185020B (en) Lyophilized viral formulations
HK1185020A (en) Lyophilized viral formulations

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20210508

Address after: Church of Christ, Barbados

Patentee after: Ankolitix Biotechnology (Barbados) Co.

Address before: alberta canada

Patentee before: ONCOLYTICS BIOTECH Inc.

TR01 Transfer of patent right
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20130828

Assignee: Hangzhou Arnold Biomedical Technology Co.,Ltd.

Assignor: Ankolitix Biotechnology (Barbados) Co.

Contract record no.: X2021990000492

Denomination of invention: Freeze dried virus preparation

Granted publication date: 20150527

License type: Exclusive License

Record date: 20210816

EE01 Entry into force of recordation of patent licensing contract